Document:

EX-10.20

 Exhibit 10.20 

CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER 

THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	Execution Copy		Confidential

 AMENDMENT NO. 1 

TO 
 LICENSE AND
COMMERCIALIZATION AGREEMENT 
 This AMENDMENT NO. 1 TO LICENSE
AND COMMERCIALIZATION AGREEMENT (“Amendment No. 1”) is made and entered into effective as of June 13, 2007, (the “Amendment No. 1 Date”)
by and between, on the one hand, BIOTIE THERAPIES CORP. (“BioTie”) and, on the other hand, MEDAREX, INC. and GENPHARM INTERNATIONAL,
INC., a wholly owned subsidiary of Medarex, Inc., (together “Medarex”), each being referred to herein as a “Party” and together, the “Parties.” 

Capitalized terms used in this Amendment No. 1 that are not otherwise defined herein shall have the meanings set forth in the Agreement
(as defined below). 
 WHEREAS, Medarex and BioTie entered into a License and Commercialization Agreement dated as of
November 21, 2006 (the “Agreement”); 
 WHEREAS, the Parties desire to amend the Agreement. 

NOW, THEREFORE, the Parties agree as follows: 

 

	1.	Amendment of the Agreement. 

 The Parties hereby agree to amend the terms of the
Agreement effective as of Amendment No. 1 .Date as provided below. 
  

	 	1.1.	New Section 1.1.5. A new Section 1.1.5 is added to Article 1 of the Agreement to read in its entirety as follows: 

“1.1.5 “Antibody” shall mean any VAP-1 Antibody and “Antibodies” shall mean more than one VAP-1 Antibody. For
the avoidance of doubt, each of a Lead Antibody, a Backup Antibody and a Licensed Antibody is a VAP-1 Antibody.” 
  

	 	1.2.	Amendment of Article 2. 

 1.2.1. The last sentence of Section 2.9 is
hereby amended to read in its entirety as follows: 
 “Within thirty (30) days after termination of the Exclusive Commercial
License with respect to the Licensed Antibody and if BioTie does not elect to make a substitution of a Backup Antibody pursuant to the last sentence of Section 2.1.2, unless the Parties agree otherwise in writing, BioTie shall destroy any and
all Antibodies, Antibody Materials, Mice Materials and Products with respect to VAP-1.” 
 1.2.2. A new Section 2.1.5 is
added to Article 2 of the Agreement to read in its entirety as follows: 
 “2.1.5 Subject to the terms and conditions of this Agreement,
Medarex hereby grants to BioTie, a worldwide, exclusive (even as to Medarex), 

  
 MDX – BTT License Amendment
No. 1 

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER 

THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

 
non-transferable, non-royalty-bearing license under the Medarex Technology, without the right to sublicense, to use solely for non-commercial internal research purposes, the hybridoma clone
designated 8C10 producing the anti-VAP-1 human monoclonal antibody also designated 8C10 (the “Transferred Clone”) during the term of the Agreement. The Parties acknowledge and agree that (i) the Transferred Clone constitutes
Mice Materials and with respect thereto is subject to the terms of Section 9.2 and the last sentence of Section 2.9(a) and (ii) the license granted under this Section 2.1.5 (a) may not be transferred or sublicensed by BioTie
to any third party; (b) is granted by Medarex [*****] being owed by BioTie to Medarex other than reimbursement by BioTie to Medarex for any costs related to the testing and shipment of the Transferred Clone.” 

 

	2.	Miscellaneous. 

  

	 	2.1.	No Other Changes. Except as expressly provided in this Amendment No. 1, all terms of the Agreement shall remain in full force and effect. 

 

	 	2.2.	Counterparts. This Amendment No. 1 may be executed in two or more counterparts, each of which shall be deemed an original, but both of which together shall constitute one and the same instrument.

 IN WITNESS WHEREOF, the Parties have caused this
Amendment No. 1 to be executed by their respective authorized officers. 
  

									
	MEDAREX, INC.				BIOTIE THERAPIES CORP.
					
	By:		 /s/ James B. Cornett
				By:		 /s/ Timo Veromaa

	Name:		James B. Cornett				Name:		Timo Veromaa
	Title:		VP, Business Development				Title:		President and CEO
				
	GENPHARM INTERNATIONAL, INC.						
					
	By:		 /s/ James B. Cornett
						
	Print Name:		James B. Cornett						
	Title:		VP, Business Development						

 MDX – BTT License Amendment No. 1 

  
 2EX-10.21

 Exhibit 10.21 

CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER 

THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

February 5, 2014 
 Dr. Timo Veromaa 

President and CEO 
 Biotie Therapies Corp. 

Joukahaisenkatu 6 
 F1-20520 Turku 

Finland 
 Re: Phase 2 Milestone 

Dear Dr. Veromaa: 
 Reference is made to the License and
Commercialization Agreement effective as of November 21, 2006, as amended (the “Agreement”) between Medarex, Inc., now a wholly-owned subsidiary of Bristol-Myers Squibb Company (“BMS”) and BioTie Therapies Corporation
(“BioTie”). 
 Pursuant to Section 3.3.1 of the Agreement, BioTie is required to pay BMS [*****] with respect to its anti-VAP1 antibody
product, MDX1352/BTT1023. 
 MDX1352/13TT1023 is currently in Phase I clinical trial and BioTie is preparing the initiation of Phase II trial in which
approximately [*****] patients will be enrolled. Due to the complexity and certain unpredictability of the outcome, BioTie seeks, and BMS hereby consents, to restructure this milestone payment, such that BioTie will make an initial,
nonrefundable instalment of [*****] pursuant to the timing specified in Section 3.3,1, followed up by a second instalment of [*****] BioTie agrees to share the results of any such analysis with BMS within 60 days of the completion of said
analysis. 
 If you are in agreement with the foregoing, please sign a duplicate original of this letter in the space provided and return it for our
records. 
  

							
	Sincerely yours,				
			
	/s/ Arthur H. Bertelsen				
			
					BioTie Therapies Corporation
	Arthur H. Bertelsen, Ph.D.						
	Vice President, Research Collaborations						 /s/ Timo Veromaa

					Name:		Timo Veromaa
					Title:		CEOEX-10.22

 Exhibit 10.22 

English Summary of Finnish language R&D loan agreements TEKES 921/05 dated November 18, 2005 and TEKES 747/08 dated September 11, 2008 (each a
Loan Agreement) by and between The Finnish Funding Agency for Technology and Innovation (the Lender) and Biotie Therapies Corp. (the Borrower). 

 

	 	•	 	Loan Capital: TEKES 921/05: EUR 2.453.000,00 and TEKES 747/08: EUR 564.000,00. 

  

	 	•	 	Term: Ten (10) years. 

  

	 	•	 	Maturity: Capital and interest to be paid annually. 

  

	 	•	 	Interest: Three (3) per cent. lower than the base rate set by the Finnish Ministry of Finance per annum, subject to minimum rate of one (1) per cent. per annum. Applicable penalty interest is the reference rate
in accordance with the Finnish Interest Rate Act plus seven percentage points. 

  

	 	•	 	Repayment of principal: First repayment date on the fifth anniversary of the loan, thereafter repayment of principal over five consecutive years in equal instalments, or a later date, if agreed with the
Lender. 

  

	 	•	 	Acceleration: The Lender may accelerate the loan (i) if the Borrower fails to use the loan proceeds in accordance with the purpose of the loan or if a material adverse event occurs; (ii) the conditions of the
loan are amended by the Finnish Government and the Borrower does not agree to comply with amended terms; (iii) the Borrower fails to repay principal or interest; (iv) the Borrower falls into insolvency or similar proceedings; or (v) the Borrower
fails to comply with the terms of the Loan Agreement. 

  

	 	•	 	Permitted use: The State Treasury may require repayment of the loan if the purpose of usage of the machinery or equipment acquired using the proceeds of the loan is changed, if the ownership of such machinery or
equipment is transferred to a third party or if insurance proceeds are paid for such machinery or equipment. 

  

	 	•	 	Other provisions: The State Treasury may deduct from the proceeds of the loan that is extended to the Borrower amounts to be used by the Treasury for set-off against any matured indebtedness of the Borrower to
the Treasury. The Lender has the right to conduct inspections relating to the applicable R&D project and related accounting. According to the general terms and conditions of the financing, the Borrower must inform any significant changes in the
ownership structure of the Borrower to Tekes. 

  

	 	•	 	Governing law: Finnish law.EX-10.23

 Exhibit 10.23 

English Summary of the Finnish language capital loan agreements by and between the Finnish Funding Agency for Technology and Innovation (Tekes) (the
Lender) and Biotie Therapies Corp. (the Borrower) listed below (each a Loan Agreement). 
  

					
	 Loan Name
	 	 Date of loan agreement
	 	 Loan Capital (EUR)

	 TEKES 469/98
	 	April 29, 1998	 	2,052,365.37
	 TEKES 713/98
	 	July 15, 1998	 	631,322.65
	 TEKES 734/98
	 	August 6, 1998	 	637,522.39
	 TEKES 40/99
	 	May 6, 1999	 	1,009,127.56
	 TEKES 970/99
	 	January 7, 2000	 	336,375.85
	 TEKES 25/00
	 	March 21, 2000	 	840,939.63
	 TEKES 421/01
	 	June 14, 2001	 	86,663.07
	 TEKES 587/01
	 	February 14, 2005	 	1,152,683.33
	 TEKES 958/01
	 	September 8, 2006	 	1,013,528.48
	 TEKES 345/02
	 	September 16, 2002	 	114,500.00
	 TEKES 354/02
	 	March 29, 2005	 	1,424,944.31
	 TEKES 232/03
	 	April 9, 2003	 	1,492,950.00
	 TEKES 233/03
	 	June 30, 2003	 	3,191,200.00
	 TEKES 975/04
	 	November 16, 2004	 	2,333,625.00

  

	 	•	 	Term: Eight (8) to ten (10) years from the first drawdown unless restricted by the terms of the capital loans. 

  

	 	•	 	Repayment of principal: Repayment of principal in instalments in accordance with the repayment schedules set out in the respective Loan Agreements, however, only if permitted in accordance with the limitation of
repayment set out in the Finnish Companies Act. All loans have become due in accordance with the repayment schedules included in the Loan Agreements. 

  

	 	•	 	Interest: One (1) per cent. lower than the base rate set by the Finnish Ministry of Finance per annum, subject to minimum rate of three (3) per cent. per annum. Applicable penalty interest is the
reference rate in accordance with the Finnish Interest Rate Act plus seven percentage points. Penalty interest is not applicable if the repayment of principal or interest has been restricted in accordance with the terms of the capital loans.

  

	 	•	 	Capital loan terms: Principal or interest for the loans can be repaid only if the requirements set out in the Finnish Companies Act have been met. As a general rule, the principal may be repaid and interest paid
only using distributable funds. To the extent the Borrower may not repay the loan, the unpaid principal and interest shall be moved to the following financial years until the loan has been repaid in full. The unpaid principal and interest shall be
repaid as soon as it is allowed. The auditor of the Borrower is obliged to monitor whether the loans may be repaid. 

  

	 	•	 	 Acceleration: The Lender may accelerate the loan (i) if a material adverse change in the conditions of the R&D project has occurred,
(ii) if the Borrower has provided false or misleading information or failed or rejected to provide information that has effect on the grounds for providing the loan, (iii) if the proceeds of the loan have not been used in accordance with
the decision or (iv) if the amounts of the loans exceed the limits set out by authorities from time to time or if the EU commission requires the repayment of the loan in part or in full. Further, the State Treasury may accelerate the loan if
the Borrower has used the loan to other purposes than those set out in the Loan Agreement or if the Borrower fails to 

	 	 
comply with the terms of the Loan Agreement (as amended from time to time), if the Borrower fails to repay principal or interest or if the Borrower falls into insolvency or similar proceedings.

  

	 	•	 	Change in conditions: The Lender may require repayment of the loan if the purpose of usage of the machinery or equipment acquired using the proceeds of the loan is changed, if the ownership of such machinery or
equipment is transferred to a third party or if insurance proceeds are paid for such machinery or equipment. 

  

	 	•	 	Other provisions: The Borrower must negotiate with the Lender if the Borrower wishes to draw other capital loans. The Lender has the right to conduct inspections relating to the applicable R&D project and
related accounting. According to the general terms and conditions of the financing, the Borrower must inform any significant changes in the ownership structure of the Borrower to Tekes. 

 

	 	•	 	Governing law: Finnish law.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}]]